Oliver Mobasser

Mr Mobasser’s representative experience includes advising:

• GSK on:
  • A strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases
  • A global license and collaboration with SpringWorks Therapeutics for development and commercialization of SpringWorks’ nirogacestat product and GSK’s Blenrep product 
  • Several early-stage clinical trial, collaboration, development, and supply arrangements
  • The divestment of its Prevacid 24HR business to Perrigo Company
  • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia
  • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group
  • The divestment of four established over-the-counter brands in eight countries to Pharma SGP
• Swedish Orphan Biovitrum AB (publ) (Sobi™) on matters including:
  • A strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million
  • A strategic licensing and collaboration agreement with Apellis Pharmaceuticals for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
  • Streamlining and simplifying the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of its participation agreement with AstraZeneca 
  • Its US$1.7 billion acquisition of CTI BioPharma Corp, a biopharmaceutical company focused on blood-related cancers and rare diseases 
• Norgine, a Netherlands-based specialty pharmaceutical company, in its US$2 billion sale to Goldman Sachs
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist
• Astorg and OPEN Health on data protection matters related to the acquisition of The CM Group, an integrated commercialization platform
• Lindsay Goldberg, on data protection matters related to its investment in MMS Holdings, a leading data-focused contract research organization
• A consortium of Astorg Asset Management, Nordic Capital, Novo Holdings — and their portfolio company eResearchTechnologies, on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
• Frontier Medicines on the data privacy aspects of its global partnership with AbbVie to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
• BC Partners on IP, contracts, data protection and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects
• Leadiant Biosciences on the sale of its assets relating to Revcovi, a pharmaceutical product for the treatment of a rare immunodeficiency disease, to Chiesi Farmaceutici
• Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services, to the global diagnostics and life sciences industries
• Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East, and Africa for a total value in excess of US$200 million
• Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product, Apealea, with Elevar Therapeutics, with a deal value of approximately US$698 million
• Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
• Permira, on contracts, regulatory, and IP matters related to the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory, two leading providers of medicinal products derived from human blood plasma
• Permira on data protection, contracts, regulatory, and IP matters related to the acquisition of Quotient Sciences, a provider of contract development and manufacturing and contract research services to pharma and biotech companies
• Quotient Sciences on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization